These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 35697228)
1. H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis. Bin-Alamer O; Jimenez AE; Azad TD; Bettegowda C; Mukherjee D World Neurosurg; 2022 Sep; 165():e251-e264. PubMed ID: 35697228 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of H3K27M-mutant diffuse gliomas with a non-midline location. Guidara S; Seyve A; Poncet D; Leonce C; Bringuier PP; McLeer A; Sturm D; Cartalat S; Picart T; Ferrari A; Hench J; Frank S; Meyronet D; Ducray F; Barritault M J Neurooncol; 2024 Sep; 169(2):391-398. PubMed ID: 38937309 [TBL] [Abstract][Full Text] [Related]
3. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors. Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957 [TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases]. Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644 [No Abstract] [Full Text] [Related]
5. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres. La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896 [TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant. Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837 [TBL] [Abstract][Full Text] [Related]
7. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker. Agarwal P; Aiyer HM Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633 [TBL] [Abstract][Full Text] [Related]
8. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847 [TBL] [Abstract][Full Text] [Related]
9. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival. Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221 [TBL] [Abstract][Full Text] [Related]
10. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma. Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690 [TBL] [Abstract][Full Text] [Related]
11. Neuroradiological, genetic and clinical characteristics of histone H3 K27-mutant diffuse midline gliomas in the Kansai Molecular Diagnosis Network for CNS Tumors (Kansai Network): multicenter retrospective cohort. Hayashi N; Fukai J; Nakatogawa H; Kawaji H; Yoshioka E; Kodama Y; Nakajo K; Uda T; Naito K; Kijima N; Okita Y; Kagawa N; Takahashi Y; Hashimoto N; Arita H; Takano K; Sakamoto D; Iida T; Arakawa Y; Kawauchi T; Sonoda Y; Mitobe Y; Ishibashi K; Matsuda M; Achiha T; Tomita T; Nonaka M; Hara K; Takebe N; Tsuzuki T; Nakajima Y; Ohue S; Nakajima N; Watanabe A; Inoue A; Umegaki M; Kanematsu D; Katsuma A; Sumida M; Shofuda T; Mano M; Kinoshita M; Mori K; Nakao N; Kanemura Y Acta Neuropathol Commun; 2024 Jul; 12(1):120. PubMed ID: 39061104 [TBL] [Abstract][Full Text] [Related]
12. Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis. Lu VM; Alvi MA; McDonald KL; Daniels DJ J Neurosurg Pediatr; 2019 Mar; 23(3):308-316. PubMed ID: 30544362 [TBL] [Abstract][Full Text] [Related]
13. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance? Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407 [TBL] [Abstract][Full Text] [Related]
14. Four methods to analyze H3K27M mutation in diffuse midline gliomas. Zhao H; Fang X; Xue B Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938 [TBL] [Abstract][Full Text] [Related]
15. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993 [TBL] [Abstract][Full Text] [Related]
16. Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases. Liu Y; Zhang Y; Hua W; Li Z; Wu B; Liu W World Neurosurg; 2019 Jun; 126():e1169-e1182. PubMed ID: 30885860 [TBL] [Abstract][Full Text] [Related]
17. H3K27M, IDH1, and ATRX expression in pediatric GBM and their clinical and prognostic significance. Uppar AM; Sugur H; Prabhuraj AR; Rao MB; Devi BI; Sampath S; Arivazhagan A; Santosh V Childs Nerv Syst; 2019 Sep; 35(9):1537-1545. PubMed ID: 31152217 [TBL] [Abstract][Full Text] [Related]
18. H3K27M-mutant glioma in thoracic spinal cord and conus medullaris with pilocytic astrocytoma morphology: case report and review of the literature. Palpan Flores A; Rodríguez Domínguez V; Esteban Rodriguez I; Román de Aragón M; Zamarrón Pérez Á Br J Neurosurg; 2024 Aug; 38(4):1020-1026. PubMed ID: 34615413 [TBL] [Abstract][Full Text] [Related]
19. H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Wang L; Li Z; Zhang M; Piao Y; Chen L; Liang H; Wei Y; Hu Z; Zhao L; Teng L; Lu D Hum Pathol; 2018 Aug; 78():89-96. PubMed ID: 29727696 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis. Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]